Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18409695 | KIT FOR BREEDING A TGEV INFECTION RESISTANT PIG AND USE THEREOF | January 2024 | January 2025 | Allow | 12 | 2 | 1 | Yes | No |
| 18381660 | VASCULARIZED ISLET AND PREPARATION METHOD THEREOF | October 2023 | February 2025 | Abandon | 16 | 2 | 0 | No | No |
| 17821754 | UMBILICAL CORD MESENCHYMAL STEM CELLS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND LUNG DEGENERATION | August 2022 | January 2025 | Abandon | 29 | 2 | 0 | No | No |
| 17850770 | HUMANIZED MOUSE MODELS FOR STUDY OF COVID-19 | June 2022 | April 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17748992 | CDC-DERIVED EXOSOMES FOR TREATMENT OF VENTRICULAR TACHYARRYTHMIAS | May 2022 | May 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17748611 | KCNV2 Variants and Their Use | May 2022 | June 2024 | Allow | 25 | 2 | 0 | Yes | No |
| 17742126 | METHODS OF CANCER TREATMENT BY INHIBITION OF VASCULOGENESIS AND GLI1 | May 2022 | January 2025 | Abandon | 32 | 3 | 0 | No | No |
| 17662627 | INTRANASALLY ADMINISTERED NEURAL STEM CELLS FOR TREATMENT OF TRAUMATIC BRAIN INJURIES | May 2022 | March 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17427513 | METHODS FOR USING TRANSCRIPTION-DEPENDENT DIRECTED EVOLUTION OF AAV CAPSIDS | July 2021 | March 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17425893 | METHOD FOR TREATING OR PREVENTING GASTROINTESTINAL BLEEDING | July 2021 | May 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17418754 | SYSTEMIC SCLEROSIS DISEASE MODEL AND USE THEREOF | June 2021 | May 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17416490 | NUCLEIC ACID APTAMER SPECIFICALLY RECOGNIZING B-LACTOGLOBULIN AND USE THEREOF | June 2021 | September 2024 | Allow | 39 | 1 | 1 | Yes | No |
| 17351150 | METHOD OF SEPARATING HEMATOPOIETIC STEM CELLS FROM UMBILICAL CORD BLOOD | June 2021 | November 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17311011 | SYSTEMS, DEVICES AND METHODS FOR IDENTIFICATION, SELECTIVE ABLATION, AND SELECTION AND COLLECTION OF SINGLE CELLS | June 2021 | November 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17293867 | METHOD OF PRESERVING CELLS FOR THERAPEUTIC USE | May 2021 | September 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17290032 | CHEMICAL ENGINEERING OF ERYTHROCYTES TO DISPLAY POLYPEPTIDES AND OTHER BIOMACROMOLECULES | April 2021 | September 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17289132 | ISOLATED NASOPHARYNGEAL CARCINOMA CELLS AND DERIVATIVES PREPARED THEREOF | April 2021 | June 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17288373 | ER TUNABLE PROTEIN REGULATION | April 2021 | June 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17226974 | SYNERGISTIC TRANSCRIPTION FACTORS TO INDUCE HIGH RESISTANCE TRANSENDOTHELIAL BARRIER D | April 2021 | December 2024 | Abandon | 44 | 1 | 1 | No | No |
| 17282425 | COMPARTMENTALIZED CELL CULTURES FOR USAGE IN HIGH CAPACITY APPLICATIONS | April 2021 | September 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17279437 | MINERALIZATION OF CELL-LADEN MATRICES | March 2021 | January 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17277618 | METHOD FOR INCREASING LENTIVIRAL VECTOR PRODUCTION | March 2021 | October 2024 | Abandon | 43 | 2 | 0 | No | No |
| 17276628 | Hair Follicle Germs, Method for Producing Hair Follicle Germs, and Method for Activating Cells Included in Hair Follicle Germs | March 2021 | July 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17187121 | PRODUCTION METHOD FOR ANIMAL MODELS WITH DISEASE ASSOCIATED PHENOTYPES | February 2021 | August 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17269223 | STEM CELL DERIVED LINEAGE BARCODING | February 2021 | January 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17268795 | METHODS AND COMPOSITIONS FOR TREATING SUBJECTS EXPOSED TO VESICANTS AND OTHER CHEMICAL AGENTS | February 2021 | May 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17268437 | CELL CULTURE DEVICE FORMING A THREE DIMENSIONAL PERFUSION NETWORK FROM A PATTERNED MATERIAL UPON EXPOSURE TO HYDROGEL | February 2021 | July 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17172005 | IGF2-CONTAINING MEDIUM FOR CULTURING MAMMALIAN EMBRYOS IN VITRO AND CULTURE METHOD | February 2021 | August 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17167744 | Microfluidic System Including Cooling Device | February 2021 | May 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17262243 | DISSOCIATION OF BIOLOGICAL SAMPLES | January 2021 | May 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17253038 | FUNCTIONAL CORTICO-SPINAL-MUSCLE ASSEMBLED SPHEROIDS | December 2020 | June 2024 | Allow | 42 | 2 | 0 | Yes | No |
| 17123057 | CELL CULTURE APPARATUS AND CELL CULTURE METHOD | December 2020 | April 2025 | Abandon | 52 | 3 | 1 | Yes | No |
| 16808932 | SEQUENTIAL INTRAVITREAL ADMINISTRATION OF AAV GENE THERAPY TO CONTRALATERAL EYES | March 2020 | January 2025 | Abandon | 58 | 4 | 1 | No | No |
| 16624663 | METHOD OF HUMAN PERIFERIC SENSORY NEURONS DIFFERENCIATION FROM HUMAN STEM CELLS AND USES THEREOF | December 2019 | March 2024 | Allow | 51 | 4 | 0 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner REGLAS, GILLIAN CHELSEA works in Art Unit 1632 and has examined 33 patent applications in our dataset. With an allowance rate of 15.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner REGLAS, GILLIAN CHELSEA's allowance rate of 15.2% places them in the 0% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by REGLAS, GILLIAN CHELSEA receive 1.27 office actions before reaching final disposition. This places the examiner in the 24% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by REGLAS, GILLIAN CHELSEA is 41 months. This places the examiner in the 5% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +83.3% benefit to allowance rate for applications examined by REGLAS, GILLIAN CHELSEA. This interview benefit is in the 100% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 16.7% of applications are subsequently allowed. This success rate is in the 7% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 50.0% of cases where such amendments are filed. This entry rate is in the 69% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants file petitions regarding this examiner's actions, 111.1% are granted (fully or in part). This grant rate is in the 98% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.